Reportedly, American multinational biopharmaceutical Amgen (AMGN) has scheduled to release its full year 2022 & fourth quarter earnings on January 31, 2023, Tuesday after the close of regular trading hours. The earnings release will be followed by a conference call hosted by CEO & Chairman Robert A. Bradway along with other members from the senior management team at 4:30 p.m. ET with the investment community.
The event can be reached at Amgen’s website, www.amgen.com. under Investors.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
On Wednesday Jan., 25, Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:
TO OUR VALUED STOCKHOLDERS:
2022 was a year of significant progress for Atossa. We focused our development efforts on advancing our breast cancer program with our patented (Z)-endoxifen, the highest potency Selective Estrogen Receptor Modifier (SERM). We currently have Phase 2 studies ongoing in the prevention and treatment settings, both focused on areas of unmet medical need. Our goal is to both help reduce the incidence of breast cancer and change the treatment paradigm for patients who are not benefiting from currently approved drugs.
In October 2022, the U.S. Food and Drug Administration (FDA) authorized the initiation of our EVANGELINE study, a Phase 2 trial of (Z)-endoxifen and Exemestane + Goserelin as neoadjuvant treatment in premenopausal women with ER+/HER2- breast cancer. While there are several FDA-approved neoadjuvant therapies for ER- breast cancers, few exist for the ER+ patients, which account for approximately 78% of breast cancers. We expect to enroll approximately 175 patients at up to 25 sites across the United States.